RCKT ROCKET PHARMACEUTICALS, INC.: institutional ownership and insider trading
186 funds reported holding $375M of ROCKET PHARMACEUTICALS, INC. in their latest 13F filings; in Q2 2026 funds net bought $8.90M, with 16 new positions and 34 funds selling out; over the last 12 months insiders bought $34.4K and sold $864K on the open market; over its last four quarters it reported revenue of $0 and net income of −$17.3M.
RCKT revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0, net income $123M, EPS 1.08
- Quarter ended Mar 31, 2026: revenue $0, net income −$47.6M, EPS -0.42
- Quarter ended Dec 31, 2025: revenue $0, net income −$42.5M, EPS -0.38
- Quarter ended Sep 30, 2025: revenue $0, net income −$50.3M, EPS -0.45
Famous investors holding RCKT
- Lee Ainslie (Maverick Capital): $13.4M, 0.1% of the portfolio
- Izzy Englander (Millennium Management): $13.7M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $3.25M, 0.0% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $2.71M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $1.08M, 0.0% of the portfolio
- Ken Griffin (Citadel Advisors): $466K, 0.0% of the portfolio
Largest institutional holders of RCKT
- RTW INVESTMENTS, LP — $60.5M
- BlackRock, Inc. (BLK) — $33.9M
- VANGUARD GROUP INC — $30.0M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $19.9M
- CITIGROUP INC (C, C-PN) — $16.6M
- MARSHALL WACE, LLP — $13.8M
- MILLENNIUM MANAGEMENT LLC — $13.7M
- Newtyn Management, LLC — $13.7M
- MAVERICK CAPITAL LTD — $13.4M
- VANGUARD CAPITAL MANAGEMENT LLC — $12.9M
Recent RCKT insider trades
- Sep 11, 2026: Wilson Martin sold 75,364 shares ($256K)
- Aug 18, 2026: Shah Gaurav sold 2,293 shares ($7.75K)
- Aug 18, 2026: Wilson Martin sold 631 shares ($2.13K)
- Aug 13, 2026: Wilson Martin sold 3,493 shares ($11.8K)
5%+ owners
- Vanguard Portfolio Management: 5.4% (Schedule 13G, filed Jul 31, 2026)